Background: Prophylaxis with low-dose aspirin may reduce the risk of pre-eclampsia (PE) if introduced in first trimester. The performance of first trimester maternal serum screening for PE using free leptin index (fLI) and PAPP-A, where fLI = leptin/leptin soluble receptor was studied.
Methods: First trimester serum samples from 126 PE pregnancies and 289 control pregnancies were studied. fLI and PAPP-A were converted into gestational age and maternal weight independent log MoM values of PAPP-A and fLI. The screening performance of markers was studied by receiver-operator-characteristics curves. The performance of population screening was estimated by Monte Carlo simulation.
Results: fLI was significantly (p < 0.001) elevated [mean log MoM 0.2165 (SD: 0.2604)] compared to controls [mean log MoM -0.0368 (SD: 0.3132)] and PAPP-A was significantly (p < 0.001) reduced [mean log MoM -0.0133 (SD: 0.2661)] compared to controls [mean log MoM 0.0474 (SD: 0.2521)] in PE pregnancies. There was no correlation between fLI and PAPP-A in control or PE pregnancies. Combined fLI and PAPP-A screening for PE had estimated population detection rates of 22% and 35% for false positives rates of 6% and 12%, respectively.
Conclusion: Combining PAPP-A and fLI improves screening performance for PE compared to single marker screening.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pd.2337 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of pre-eclampsia using maternal hemodynamic parameters at 12 + 0 to 15 + 6 weeks.
Ultrasound Obstet Gynecol
January 2025
Department of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Objectives: To compare the maternal hemodynamic profile at 12 + 0 to 15 + 6 weeks' gestation in women who subsequently developed pre-eclampsia (PE) and those who did not, and to assess the screening performance of maternal hemodynamic parameters for PE in combination with the Fetal Medicine Foundation (FMF) triple test, including maternal factors (MF), mean arterial pressure (MAP), uterine artery pulsatility index and placental growth factor.
Methods: This was a prospective case-control study involving Chinese women with a singleton pregnancy who underwent preterm PE screening at 11 + 0 to 13 + 6 weeks' gestation using the FMF triple test, between February 2020 and February 2023. Women identified as being at high risk (≥ 1:100) for preterm PE by the FMF triple test were matched 1:1 with women identified as low risk (< 1:100) for maternal age ± 3 years, maternal weight ± 5 kg and date of screening ± 14 days.
Prenatal ultrasound diagnosis and quality control of fetal nuchal translucency.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
April 2024
Department of Obstetrics Ultrasonography Room, Xiangya Hospital, Central South University, Changsha 410008, China.
Objectives: In clinical ultrasound examinations, it is challenging to perform quality control on the images of each fetal nuchal translucency (NT) and crown-rump length (CRL). However, small measurement differences can increase the probability of false-positive or false-negative diagnosis. Therefore, it is necessary to establish a quality control system for fetal NT examination.
View Article and Find Full Text PDFBiomarkers in the prediction of complications in pregnancy after assisted reproductive technology.
Int J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong, SAR, China.
Objectives: To compare the temporal changes in mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), placental growth factor (PlGF), and soluble fms-like tyrosine kinase-1 (sFlt-1) across gestation between assisted reproductive technology (ART) pregnancies complicated with great obstetrical syndromes (GOS) or gestational diabetes (GDM) ± large-for-gestational-age (LGA) fetus, and uncomplicated ART pregnancies.
Methods: This was a prospective longitudinal study of 143 women with singleton pregnancies who conceived through ART at the Department of Obstetrics and Gynecology, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR between December 2017 and January 2020. The participants were followed up at 6-6, 11-13, 20-24, 30-34, and 35-37 weeks for the measurement of MAP, UtA-PI, PlGF, and sFlt-1.
Associations of Serum Perfluoroalkyl Substances and Placental Human Chorionic Gonadotropin in Early Pregnancy, Measured in the UPSIDE Study in Rochester, New York.
Environ Health Perspect
April 2024
Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
Background: Per- and polyfluoroalkyl substances (PFAS) are widely detected in pregnant women and associated with adverse outcomes related to impaired placental function. Human chorionic gonadotropin (hCG) is a dimeric glycoprotein hormone that can indicate placental toxicity.
Objectives: Our aim was to quantify the association of serum PFAS with placental hCG, measured as an intact molecule (hCG), as free alpha-() and beta-subunits (), and as a hyperglycosylated form (h-hCG), and evaluate effect measure modification by social determinants and by fetal sex.
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer.
J Gynecol Oncol
November 2024
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Article Synopsis
- The study aimed to compare the effectiveness, safety, and tolerability of a treatment combining dose-dense paclitaxel and carboplatin with bevacizumab (ddTC+Bev) versus dose-dense paclitaxel and carboplatin alone (ddTC) for advanced ovarian cancer.
- A total of 134 patients treated with either ddTC+Bev or ddTC were analyzed, showing that the ddTC+Bev group had better progression-free survival (PFS) at first glance, but the results were less significant when adjusted for potential biases.
- The study concluded that there wasn't enough evidence to prove that adding bevacizumab improves patient outcomes, indicating the need for further research with larger
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!